Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including … Read more
Bio Preventive Medicine Corp. (6810) - Total Assets
Latest total assets as of June 2025: NT$473.47 Million TWD
Based on the latest financial reports, Bio Preventive Medicine Corp. (6810) holds total assets worth NT$473.47 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio Preventive Medicine Corp. - Total Assets Trend (2020–2024)
This chart illustrates how Bio Preventive Medicine Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bio Preventive Medicine Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
Bio Preventive Medicine Corp.'s total assets of NT$473.47 Million consist of 69.2% current assets and 30.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 66.6% |
| Accounts Receivable | NT$603.00K | 0.1% |
| Inventory | NT$1.40 Million | 0.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$11.69 Million | 2.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Bio Preventive Medicine Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio Preventive Medicine Corp.'s current assets represent 69.2% of total assets in 2024, a decrease from 72.5% in 2020.
- Cash Position: Cash and equivalents constituted 66.6% of total assets in 2024, up from 57.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 9.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 2.2% of total assets.
Bio Preventive Medicine Corp. Competitors by Total Assets
Key competitors of Bio Preventive Medicine Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bio Preventive Medicine Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bio Preventive Medicine Corp. generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bio Preventive Medicine Corp. is currently not profitable relative to its asset base.
Bio Preventive Medicine Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.06 | 1.41 | 4.97 |
| Quick Ratio | 18.98 | 1.40 | 4.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$297.16 Million | NT$ 33.17 Million | NT$ 75.95 Million |
Bio Preventive Medicine Corp. - Advanced Valuation Insights
This section examines the relationship between Bio Preventive Medicine Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 100.1% |
| Total Assets | NT$529.71 Million |
| Market Capitalization | $4.97K USD |
Valuation Analysis
Below Book Valuation: The market values Bio Preventive Medicine Corp.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bio Preventive Medicine Corp.'s assets grew by 100.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bio Preventive Medicine Corp. (2020–2024)
The table below shows the annual total assets of Bio Preventive Medicine Corp. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$529.71 Million | +100.15% |
| 2023-12-31 | NT$264.66 Million | -3.10% |
| 2022-12-31 | NT$273.12 Million | +78.70% |
| 2021-12-31 | NT$152.83 Million | -30.99% |
| 2020-12-31 | NT$221.48 Million | -- |